9 research outputs found
Synergistic activity of methanolic extract of Thespesia populnea (malvaceae) flowers with oxytetracycline
The object of this study was to formulate new, cost effective anti-microbial combination for multidrug resistant diseases based on the synergistic activity of oxytetracycline with methanolic extract of Thespesia populnea (Malvaceae) a medicinal plant common in South India. The MIC of methanolic extracts in combination with oxytetracycline using 12 different both gram positive and gram negative bacteria was found to be around (62.5 µg/mL to 1000 µg/mL). The synergistic activity was verified using Kirby and Bauer techniques. 83.3% shows synergistic activity against all 12 different bacteria both gram positive and gram negative species. The highest synergism rate was attained against Shigella boydii (ATCC8700)
Diaphragmatic Rupture Secondary to Blunt Thoracic Trauma
[West J Emerg Med. 2013;14(5):435–436.
Synergistic activity of methanolic extract of Thespesia populnea (malvaceae) flowers with oxytetracycline
Diaphragmatic Rupture Secondary to Blunt Thoracic Trauma
[West J Emerg Med. 2013;14(5):435–436.
Recommended from our members
Pediatric Solid Tumors and Second Malignancies: Characteristics and Survival Outcomes
To examine the incidence, characteristics, and outcomes for second malignancies following the diagnosis of a primary solid tumor in pediatric patients.
The Surveillance, Epidemiology, and End Results (SEER) database was queried from 1973 to 2005, excluding recurrences, in patients <20 y.
A total of 31,685 cases of pediatric solid malignancies were identified. Overall, 177 patients were diagnosed with a unique second malignancy before the age 20 (0.56%) The mean follow-up was for 8.5 y (2 mo–30.8 y). Mean age at diagnosis of the primary tumor was 7.7 y. The most common primary malignancies were CNS tumors (22.5%), followed by soft tissue sarcoma (15.8%), retinoblastoma (14.1%), and bone tumors (13%). Hematologic malignancies (35.5%) were the most common second malignancies noted in the cohort, followed by bone tumors (18%) and soft tissue sarcomas (15%). Hematologic malignancies had a shorter latency (3.1 y) compared with solid second tumors (11.6 y). The overall 10-y survival for the entire cohort was 41.5%. For most tumor categories, development of a secondary malignancy was associated with lower 5- and 10-y survival than expected.
CNS tumors, retinoblastoma, and soft tissue sarcomas in children are the most common solid primary tumors, with an increased risk of a second malignancy. Leukemia is the most common second malignancy seen in pediatric solid tumors. Second malignancies are associated with significantly reduced survival rates compared with the general childhood cancer population